Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genfit SA (GNFT)
NASDAQ:GNFT
Holding GNFT?
Track your performance easily
GNFT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.08 - $6.42
Previous Close$4.31
Volume705.00
Average Volume (3M)13.82K
Market Cap
$218.33M
Enterprise Value$210.26M
Total Cash (Recent Filing)€77.79M
Total Debt (Recent Filing)€70.18M
Price to Earnings (P/E)8.9
Beta0.56
Next Earnings
Apr 10, 2025EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding49,834,983
10 Day Avg. Volume5,947
30 Day Avg. Volume13,820
Standard Deviation0.20
R-Squared0.10
Alpha-0.00515
Financial Highlights & Ratios
Price to Book (P/B)3.17
Price to Sales (P/S)13.17
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.50Price Target Upside147.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Genfit SA News
PremiumCompany Announcements
Genfit Advances Liver Disease Programs Amid Promising Developments
PremiumCompany Announcements
Genfit’s Revenue Surge Driven by Key Milestone
PremiumCompany Announcements
Genfit’s Iqirvo Wins EU Approval for Liver Condition
PremiumCompany Announcements
GENFIT SA Showcases Robust 2024 Financial Health
PremiumCompany Announcements
Genfit SA Expands R&D, Gains FDA Approval
PremiumCompany Announcements
GENFIT’s Drug Nears EU Market Approval
PremiumCompany Announcements
GENFIT Announces Mid-Year Liquidity FiguresOwnership Overview
―
Insiders
<0.01% Mutual Funds
0.10% Other Institutional Investors
99.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GNFT FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was $3.08 and its highest was $6.42 in the past 12 months.
What is Genfit SA’s market cap?
Currently, no data Available
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Apr 10, 2025 which is in 139 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Sep 19, 2024. The company reported $0.591 earnings per share for the quarter, beating the consensus estimate of $0.337 by $0.254.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -$0.46.
How many shares outstanding does Genfit SA have?
Genfit SA has 49,992,786 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of $0.591 in its last earnings report, beating expectations of $0.337. Following the earnings report the stock price went up 15.513%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in GNFT
---
Genfit SA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (147.64% Upside)
$10.50 (147.64% Upside)
Blogger Sentiment
Bullish
GNFT Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 10.9%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.60%
12-Months-Change
Fundamentals
Return on Equity
26.13%
Trailing 12-Months
Asset Growth
-1.36%
Trailing 12-Months
Company Description
Genfit SA
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.
---
GNFT Earnings Call
Q2 2023
0:00 / 0:00
---
GNFT Stock 12 Month Forecast
Average Price Target
$10.50
▲(147.64% Upside)
Technical Analysis
Best Analysts Covering GNFT
1 Year
1 Year Success Rate
8/16 ratings generated profit
1 Year Average Return
+0.58%
reiterated a buy rating last month
Copying Ed Arce's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.58% per trade.
---